51%
Proven Results With ORIAHNN
See how ORIAHNN was studied in women like you
ORIAHNN is an oral treatment proven to help lighten heavy periods due to uterine fibroids
ORIAHNN was studied in two 6-month clinical trials, including premenopausal women aged 25-53 with heavy periods due to uterine fibroids.
~7 in 10
women experienced lighter periods taking ORIAHNN*
This meant bleeding volume was reduced by at least 50% from the start of the trial, and to below 80 mL (about 1/3 of a cup) at the final month of treatment.
*Compared with about 1 in 10 women taking placebo.
Average period bleeding was reduced by 89% (-188 mL) at Month 6†
†ORIAHNN values from the start of Trial 2 to Month 6 compared with an increase of about 9% (12 mL) in women taking placebo.
From the start of Trial 1 to Month 6, average bleeding was reduced by about 81% (189 mL) compared with an average decrease of about 3% (9 mL) in women taking placebo.
Start of Trial‡
before starting ORIAHNN
Month 1‡
after taking ORIAHNN for 1 month
86%
Month 3‡
after taking ORIAHNN for 3 months
89%
Month 6‡
after taking ORIAHNN for 6 months
‡ORIAHNN values for Trial 2. Placebo values were 256 mL at the start of the trial and resulted in 6% (16 mL) average decrease at Month 1, 12% (27 mL) average decrease at Month 3, and 9% (12 mL) average increase at Month 6.
For Trial 1, ORIAHNN values were 238 mL at the start of the trial and resulted in a 52% (124 mL) average decrease at Month 1, 82% (187 mL) average decrease at Month 3, and 81% (189 mL) average decrease at Month 6. Placebo values were 259 mL at the start of the trial and resulted in 13% (33 mL) average decrease at Month 1, 4% (0.1 mL) average decrease at Month 3, and 3% (9 mL) average decrease at Month 6.
5 in 10 women
taking ORIAHNN for 6 months saw an increase in their hemoglobin levels.§
5 in 10 women
taking ORIAHNN for 6 months saw an
increase in their hemoglobin levels.§
Before starting ORIAHNN, 100 women in the 2 ORIAHNN clinical trials had low levels of hemoglobin, which can be a sign of anemia. Most of these women (90%) also took an iron supplement. ORIAHNN was not specifically studied in women with anemia.
§Compared with nearly 2 in 10 women taking placebo.
In Trial 2, 50% of the 48 women taking ORIAHNN with a baseline hemoglobin of ≤10.5 g/dL achieved an increase of >2 g/dL in Hgb at Month 6 compared with 21% of the 24 women taking placebo.
In Trial 1, 62% of the 52 women taking ORIAHNN with a baseline hemoglobin of ≤10.5 g/dL achieved an increase of >2 g/dL in Hgb at Month 6 compared with 16% of the 31 women taking placebo.
Ready to talk with your doctor about ORIAHNN?
ORIAHNN was studied in a broad range of women
The 790 women who participated in the ORIAHNN clinical trials all experienced heavy periods due to uterine fibroids. Here’s a look at their diverse characteristics:
Race included
68% Black/African American
29% White/Caucasian
3% Other races/ethnicities
Fibroids varied
in both size
and location
Bleeding per period at the
start of the trials ranged
from 1/3 of a cup to 5 cups
Age ranged from
25 to 53 years old
Weight ranged from
108 lbs to 355 lbs
Trials included
women with and without children